gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Melanoma antigen family A, 3

This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: MAGE-1, MART-1, CAN, tyrosinase, POLYMERASE
Papers on MAGE-3
Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
El-Labbody et al., Cairo, Egypt. In World J Gastroenterol, 2015
The expression levels of the CSCs markers (CD133 and CD90) as well as telomerase, melanoma antigen encoding gene 1 (MAGE1) and MAGE3 were assessed by RT-PCR and quantitative real-time polymerase chain reactions.
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.
Maccalli et al., Milano, Italy. In Oncoimmunology, 2014
NA17.A2 and MAGE-3.A1 peptides were used as vaccine.
Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization.
Tokura et al., Hamamatsu, Japan. In J Dermatol Sci, 2014
METHODS: We performed PPI in 59 patients undergoing advanced MM with Melan-A, tyrosinase, MAGE-2, MAGE-3 and gp-100 peptides based on HLA typing in individuals.
Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Samarzija et al., In Tumori, 2014
A statistically higher immunohistological expression rate of MAGE-A3/4 was found in squamous cell carcinoma (P <0.001) and a significantly higher amount of tumor necrosis was observed in tumors with MAGE-3 expression (P = 0.001), but no correlation with positive lymph nodes was found.
Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy.
Whiteside et al., Warsaw, Poland. In Gynecol Obstet (sunnyvale), 2013
Exosomes isolated from OvCa patients's plasma carried TGF-β1 and MAGE3/6, which distinguished OvCa patients from those with benign tumors and NC.
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Pawelec et al., Tübingen, Germany. In J Clin Oncol, 2012
PURPOSE: To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis.
MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases.
Jeon et al., Taegu, South Korea. In Oncol Rep, 2012
Report MAGEA1-A6 expression and MAGE A3 methylation in sputum suggests presence of lung cancer cells or precancerous cells.
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Sakaguchi et al., Ōsaka, Japan. In Blood, 2012
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Usefulness of the melanoma antigen gene (MAGE) in making the differential diagnosis between pleomorphic adenoma and adenoid cystic carcinoma.
Lim et al., Kwangju, South Korea. In J Otolaryngol Head Neck Surg, 2012
the expression of MAGE, as confirmed in the RT-PCR analysis, could be used as an alternative method for the early diagnosis of salivary gland tumours.
MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma.
Miranda et al., Mexico. In Hematology, 2011
Data indicate the association of MAGE-A3 expression and poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients.
Immunotherapy for melanoma.
Weber, Tampa, United States. In Curr Opin Oncol, 2011
The development of vaccines that include agonists of various immune signaling like the MAGE-3 ASCI has also revived the field of cancer vaccines.
MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression.
Longley et al., Madison, United States. In Plos One, 2010
Expression of MAGE I proteins, MAGE-A3 or MAGE-C2, relieved repression of a reporter gene by ZNF382 and MAGE I expression relieved KAP1 mediated ID1 repression.
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
McMasters et al., Louisville, United States. In J Clin Oncol, 2006
RT-PCR analysis was performed using four markers: tyrosinase, MART1, MAGE3, and GP-100.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
Boon et al., Brussels, Belgium. In J Clin Oncol, 2006
PURPOSE: To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs).
Immunogenicity of human neuroblastoma.
Pistoia et al., Genova, Italy. In Ann N Y Acad Sci, 2004
Here we shall review the work carried out in our lab in recent years and show that NB cells express tumor-associated antigens, such as MAGE-3, but lack constitutive expression of costimulatory molecules and surface HLA class I and II molecules.
Dendritic cells: controllers of the immune system and a new promise for immunotherapy.
Palucka et al., Dallas, United States. In Novartis Found Symp, 2002
DCs were pulsed with MART1, tyrosinase, MAGE3, gp100 and Flu-MP peptides, and KLH.
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Boon et al., Brussels, Belgium. In Immunol Rev, 2002
To establish whether there is a correlation between tumoral regressions and T-cell responses against the vaccine antigen, we evaluated the responses of patients vaccinated with a MAGE-3 antigenic peptide or a recombinant virus coding for the peptide.
[Antitumor vaccines: conception, development and evaluation in humans].
Moingeon, France. In Ann Pharm Fr, 2002
A series of phase I/II clinical studies evaluating ALVAC recombinants carrying either the CEA, p53, MAGE1 or MAGE3 genes, administered through the subcutaneous, intradermal or intravenous routes, has shown that this approach is safe and can induce tumor-specific antibody or T cell responses in at least some of the patients.
Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.
Hoon et al., Santa Monica, United States. In J Clin Oncol, 1999
Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&E staining and IHC, for melanoma metastases.
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
van der Bruggen et al., Brussels, Belgium. In Immunity, 1995
Some of them are encoded by genes MAGE-1 and MAGE-3, which are not expressed in normal tissues except in testis.
share on facebooktweetadd +1mail to friends